A5085368557- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Immune cells in cancer
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Genetic factors in colorectal cancer
- Whipple's Disease and Interleukins
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Morinda citrifolia extract uses
- Endoplasmic Reticulum Stress and Disease
- Malaria Research and Control
- Pharmacological Effects of Natural Compounds
- Bioactive Compounds and Antitumor Agents
- Cell death mechanisms and regulation
- HIV/AIDS drug development and treatment
- Hematopoietic Stem Cell Transplantation
- Ear and Head Tumors
- Immunodeficiency and Autoimmune Disorders
- Cancer and Skin Lesions
- Pain Mechanisms and Treatments
- Histone Deacetylase Inhibitors Research
Universidad de Oviedo
2018-2024
Instituto de Investigación Sanitaria del Principado de Asturias
2018-2024
Instituto de Investigación Biosanitaria de Granada
2018-2021
EntreChem (Spain)
2019
The inclusion of monoclonal antibodies targeting immune checkpoints such PD-1/PD-L1 or CTLA-4 has revolutionized the landscape anti-cancer therapy. However, PD-1 and blockade failed to achieve clinical benefit in CLL, thus attention been focused on emerging this malignancy. LAG-3 is an checkpoint receptor that negatively regulates T cell-mediated responses by inducing hyporesponsive state, promoting tumor escape. Patients with chronic lymphocytic leukemia (CLL) develop a profound suppression...
Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as powerful tool to reinvigorate antitumor responses. Herein, we analyzed the role of novel inhibitory BTLA its ligand, HVEM, in regulation leukemic natural killer (NK) cells CLL. Flow cytometry analyses showed that expression upregulated on NK from patients with CLL,...
One of the cardinal features chronic lymphocytic leukemia (CLL) is its association with a profound immunosuppression. NK cell function markedly impaired in CLL patients, who show significant dysregulation expression activating and inhibitory receptors. Here, we analyzed role novel receptor Ig-like transcript 2 (ILT2, also termed LIR-1, LILRB1) regulation cells CLL. Our results that ILT2 was significantly decreased on leukemic increased particularly those advanced disease bad prognostic...
Abstract Patients with chronic lymphocytic leukemia (CLL) progressively develop marked immunosuppression, dampening innate and adaptive-driven antitumor responses. However, the underlying mechanisms promoting immune exhaustion are largely unknown. Herein, we provide new insights into role of BTLA/HVEM axis defects in T cell-mediated responses against leukemic cells. Increased expression BTLA, an inhibitory checkpoint, was detected on surface CD4 + CD8 lymphocytes patients CLL. Moreover, high...
Lectin-like transcript 1 (LLT1) expression by tumor cells contributes to immune evasion, thereby emerging as a natural killer (NK) cell-mediated immunotherapeutic target. This study is the first investigate LLT1 (encoded CLEC2D gene) in head and neck cancers ascertain its impact on patient prognosis. was analyzed immunohistochemistry homogeneous cohort of human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinomas (OPSCC), correlated with clinical data. Results were further...
Abstract The systemic administration of interleukin-16 (IL-16, 3–30 ng/kg) induced thermal hyperalgesia in mice, that was prevented by the acute injection an anti-CD4 antibody (1 µg/kg), depletion circulating white blood cells cyclophosphamide or specific reduction CD4 + provoked a high dose (30 µg/mouse, 24 h before). IL-16-induced locally inhibited after intraplantar (i.pl.) non-selective cyclooxygenase (COX) inhibitor diclofenac, COX-1 SC-560, COX-2 celecoxib, TRPV1 antagonist capsazepine...
Glioblastoma stands as the most frequent primary brain tumor. Despite multimodal therapy for glioblastoma patients, survival rate is very low, highlighting need novel therapies that improve patient outcomes. Immune checkpoint blockade strategies are achieving promising results in a myriad of tumors and several studies have reported its efficacy at preclinical level. ILT2 immune exerts an inhibitory effect via interaction with classical non-classical HLA class-I molecules. Herein, we report...
To explore the mechanisms involved in transformation of analgesia produced by low doses CCL4 (pg/kg) to hyperalgesia when higher (ng/kg) are administered mice.The unilateral hot plate test was used assess thermal nociception. CD3+, CD4+ or CD8+ blood cells were depleted with selective antibodies. Expression CCR5 and IL-16 lymphocytes studied flow cytometry levels measured ELISA. CD8 detected immunofluorescence.IL-16 expression demonstrated T-lymphocytes cytometry. Furthermore, CCL4-induced...
B-cell receptor (BCR)-dependent signaling is central for leukemia homeostasis, as underscored by the promising clinical results obtained in patients with chronic lymphocytic (CLL) treated novel agents targeting components of this pathway. Herein, we demonstrate that mithralog EC-7072 displays high ex vivo cytotoxic activity against cells from CLL independently high-risk prognostic markers and IGHV mutational status. was significantly less toxic T NK did not alter production immune effector...
<title>Abstract</title> The systemic administration of interleukin-16 (IL-16, 3-30 ng/kg, 1 h before) induced thermal hyperalgesia in mice, that was prevented by the acute injection an anti-CD4 antibody (1 µg/kg), depletion circulating white blood cells cyclophosphamide (50 mg/kg, 72 and 24 or specific reduction CD4<sup>+</sup> provoked a high dose (30 µg/mouse, before). IL-16-induced locally inhibited after intraplantar (i.pl.) non-selective cyclooxygenase (COX) inhibitor diclofenac, COX-1...